Tumor necrosis factor alpha (TNFα) plays a key role in the pathogenesis of rheumatoid arthritis (RA).Blockade of TNFα by monoclonal antibody has been widely used for the therapy of RA since 1990s;however,mechanism of efficacy and potential safety concerns of the treatment are still not fully understood.This study sought to establish a transgenic arthritic mouse model by overexpressing human TNFα (hTNFα) and apply the model to evaluate therapeutic consequences of TNFα inhibitants.The transgenic mouse line (TgTC) with FVB background was generated by incorporating 3-modified hTNFα gene sequences.